Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia gravis, but long-term results will be key.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/self-administered-med-shows-rapid-benefit-mg-2025a1000u5x?src=rss
Author :
Publish date : 2025-11-03 15:16:00
Copyright for syndicated content belongs to the linked Source.
